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In studies comparing regular versus on-demand treatment for patients with mild per-
sistent asthma, on-demand treatment seems to have a similar efﬁcacy on clinical and
functional outcomes, but it does not suppress chronic airway inﬂammation or airway
hyper-responsiveness (AHR) associated with asthma. Data on the efﬁcacy of a continu-
ous treatment with inhaled corticosteroids (ICS) in preventing the progression of asthma
are conﬂicting. There is the possibility that patients without a regular treatment with ICS
may develop a more severe asthma associated with airway structural changes (remodel-
ing) and a progressive loss of lung function. However, the possible clinical and functional
consequences of persistent, not controlled, airway inﬂammation in patients with asthma
have to be established. Assessment of asthma control should include inﬂammatory out-
comes, such as fraction of exhaled nitric oxide and sputum eosinophil counts. Until the
relationships between symptoms, lung function tests, AHR, airway inﬂammation, exacer-
bations, and airway remodeling are clariﬁed, regular treatment seems to be generally more
appropriate than on-demand treatment to warrant a greater control of asthma. Select sub-
groups of patients with mild asthma who are well controlled by regular treatment might
adopt the on-demand treatment plan as an intermediate step toward the suspension of
controller medication. The increasing evidence for heterogeneity of asthma, the growing
emphasis on asthma subphenotypes, including molecular phenotypes identiﬁed by omics
technologies, and their possible implications for different asthma severity and progression
and therapeutic response, are changing the paradigm of treating patients with asthma
only based on classiﬁcation of their disease severity to a pharmacological strategy more
focused on the individual asthmatic patient. Pharmacological treatment of asthma is going
toward a personalized approach.
Keywords: asthma, airway inflammation, airway remodeling, inhaled corticosteroids, leukotriene receptor antag-
onists, non-invasive biomarkers, pharmacological treatment
INTRODUCTION
Asthma is characterized by chronic airway inﬂammation, which
has a central pathophysiological role. Asthma control is the pri-
mary goal of pharmacological treatment of patients with asthma.
The most effective drugs for asthma control are inhaled corticos-
teroids (ICS), which are effective anti-inﬂammatory drugs. Cur-
rent guidelines recommend daily long-term controller medica-
tions in patients with persistent asthma (NAEPP National Asthma
Education and Prevention Program: Expert Panel Report III, 2007;
GINA Global Initiative for Asthma, 2010), including those with
mild asthma, but some studies reported low rates of compli-
ance with recommendations (Gupta and Weiss, 2009; Kandane-
Rathnayake et al., 2009). Continuous treatment with ICS, alone
or in combination, is required in patients with moderate persis-
tent asthma and high-dose of ICS and/or oral corticosteroids in
combination with other drugs are required in patients with severe
asthma, but regular treatment of patients with mild persistent
asthma is not often undertaken and some studies demonstrated
that the effect of regular or on-demand treatment on functional
end-points is equivalent (Boushey et al., 2005; Papi et al., 2007).
The need for continuous treatment with anti-inﬂammatory drugs,
mainly ICS or leukotriene receptor antagonists (LTRA), in patients
with mild persistent asthma is based on the fact that uncontrolled
persistent airway inﬂammation might lead to airway remodel-
ing with consequent decrease in lung function, worsen of asthma
symptoms, and increase in asthma exacerbations and requirement
of bronchodilators as rescue medications (Canonica, 2006; Mur-
ray,2008).However, althoughplausible and likely, the linkbetween
persistent airway inﬂammation and airway remodeling has not
been deﬁnitively established and their relationships are complex
andnot completely known (Bush,2008). This is partially due to the
limitations of predictive experimental models for airway remod-
eling, the difﬁculties of performing studies of airway remodeling
in patients with asthma, which requires bronchoscopic and biop-
tic studies, the relative short duration of asthma clinical trials, the
fact that assessment of anti-asthmatic drug efﬁcacy is principally
based on clinical and functional outcomes, and the relative lack
of validated biomarkers or surrogate markers of airway inﬂam-
mation. This review summarizes the pharmacological proﬁles of
anti-asthmatic drugs indicated in patients with mild persistent
www.frontiersin.org July 2011 | Volume 2 | Article 35 | 1
Montuschi Pharmacological treatment of mild persistent asthma
asthma,presents newoutcomeswhich reﬂect airway inﬂammation
in randomized clinical trials, focuses on pharmacological strate-
gies and unresolved issues related to treatment of patients with
mild persistent asthma, and emphasizes the need for a tailored,
personalized, approach to pharmacological treatment of patients
with asthma.
DRUGS FOR PATIENTS WITH MILD PERSISTENT ASTHMA
Inhaled corticosteroids are the mainstay of asthma treatment. The
preferred long-term controller drugs in patients with mild per-
sistent asthma are ICS at low-doses (NAEPP National Asthma
Education and Prevention Program: Expert Panel Report III, 2007;
GINA Global Initiative for Asthma, 2010). Alternatively, LTRAs,
mainly montelukast, can be used as mono-therapy in respon-
ders (NAEPP National Asthma Education and Prevention Pro-
gram: Expert Panel Report III, 2007). Chromones are seldom
prescribed (NAEPP National Asthma Education and Prevention
Program: Expert Panel Report III, 2007;GINAGlobal Initiative for
Asthma, 2010). This fact can be explained by the limited efﬁcacy of
chromones, but largely relies on total absence of interest of phar-
maceutical industry in this class of drugs that unjustiﬁably affects
their prescription. This is acknowledged by current guidelines
that still recommend chromones as an alternative mono-therapy,
particularly in children with mild persistent asthma in whom a
non-steroid drug can be preferred (NAEPP National Asthma Edu-
cation and Prevention Program: Expert Panel Report III, 2007).
Theophylline is not generally administered as mono-therapy, but
its combination with a low-dose of ICS can be more effective and
safer than high-doses of ICS in patients with moderate persistent
asthma (Evans et al., 1997).
INHALED CORTICOSTEROIDS
Inhaled corticosteroids currently available for asthma treatment
include beclomethasone dipropionate, budesonide, ciclesonide,
ﬂunisolide, ﬂuticasone propionate, mometasone furoate, and tri-
amcinolone acetonide (NAEPP National Asthma Education and
Prevention Program: Expert Panel Report III, 2007; GINA Global
Initiative for Asthma, 2010). In patients with asthma, regu-
lar treatment with ICS improves all clinical, functional, and
patient reported outcomes including improvement in lung func-
tion (Pauwels et al., 2003; O’Byrne et al., 2006), reduced frequency
and severity of daytime asthma symptoms (Berger et al., 2009),
decreased incidence of nighttime awakenings (Berger et al., 2009),
decreased use of short-acting β2-adrenergic agonists (SABAs)
for symptom relief (Berger et al., 2009), improvement of the
quality of life (Berger et al., 2009) and decreased risk of acute
asthma exacerbations (Pauwels et al., 1997, 2003). In two double-
blind trials, early initiation of budesonide in mild persistent
asthma was associated with reduced risk of severe asthma exac-
erbation and improved pulmonary function in comparison with
placebo (Pauwels et al., 2003; O’Byrne et al., 2006). By reduc-
ing airway hyper-responsiveness (AHR), treatment with ICS may
target the basic features of the airways that make them asth-
matic, reducing their high sensitivity to all triggers of asthma.
ICS suppress asthmatic inﬂammation with markers of airway
inﬂammation, such as fraction of exhaled nitric oxide (FENO)
concentrations (Kharitonov et al., 2002), andAHR (Sovijärvi et al.,
2003) that return to baseline approximately 1 and 2weeks after ICS
withdrawal, respectively.
In the OPTIMA trial, patients with mild-to-moderate asthma
treated with inhaled budesonide for 1 year had a reduced rate of
severe exacerbations,dayswith asthma symptoms,andpoorly con-
trolled asthma days and nights in comparisonwith subjects treated
with placebo (O’Byrne et al., 2001).
In the inhaled Steroid Treatment As Regular Therapy in early
asthma (START) study, more than 7000 patients with new-onset
asthmawere treatedwith inhaledbudesonide or placebo for 3 years
and budesonide reduced the number of severe exacerbations and
improved forced expriratory volume in one second (FEV1) in
comparison with placebo (Pauwels et al., 2003).
The efﬁcacy of ICS has also been proved in infants and
preschool-aged children (<5 years of age) with recurrent wheez-
ing or asthma, according to the results of a published meta-
analysis (Castro-Rodriguez and Rodrigo, 2009). The study ana-
lyzed data from 29 randomized controlled trials comparing ICS
versus placebo in 3592 children: patients who received ICS had
signiﬁcantly less wheezing/asthma exacerbations than those on
placebo and this effect was independent of age, atopic condi-
tion, type of ICS used, and study duration. In addition, children
treated with ICS had more clinical (change in symptom score) and
functional [change in peak expiratory ﬂow (PEF) and FEV1 from
baseline] improvement than those on placebo (Castro-Rodriguez
and Rodrigo, 2009).
Inhaled corticosteroids also reduce hospitalizations and mor-
tality from asthma (Donahue et al., 1997; Suissa et al., 2000), but
conﬂicting results have been reported on the effects of long-term
treatment with ICS in preventing lung function decline in both
adults (Pauwels et al., 2003; Boushey et al., 2005; O’Byrne et al.,
2009) and children (Agertoft and Pedersen, 1994; Anonymous,
2000) with asthma. Part of this discrepancy could be due to differ-
ences in time and duration of asthma prior to starting therapeutic
intervention with ICS (Agertoft and Pedersen, 1994; Anonymous,
2000). The ideal population to be targeted could be represented
by patients with mild persistent asthma (Murray, 2008). Not all
patients with asthma respond to ICS. Up to 35% of patients who
do not experience improvements in FEV1 and/or AHR (Szeﬂer
et al., 2002) with ICS has been reported. Asthmatic phenotypes
characterizedby airwayneutrophilic inﬂammation are less likely to
respond to ICS than asthmatic patients with elevated eosinophilic
inﬂammation. Airway neutrophilic inﬂammation is more typical,
although not exclusive, of acute asthma exacerbation and severe
asthma and less frequent in patients with mild persistent asthma
(Wenzel, 2006; Gibson, 2009). In addition, patients with asthma
who smoke may be relatively resistant to the effects of ICS at low-
dose (Tomlinson et al., 2005; Lazarus et al., 2007). Finally, genetic
differences may be responsible for steroid-resistance.
Treatment with ICS can have topical and systemic side effects.
Weak or hoarse voice and candidiasis are the most frequent local
effects (NAEPP National Asthma Education and Prevention Pro-
gram: Expert Panel Report III, 2007; GINA Global Initiative for
Asthma, 2010). The risk of developing adverse systemic effects
fromICS is affectedby several factors, includingdose,drugdelivery
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system used, and inter-individual differences in the response to
the corticosteroids. Apart from bruising, long-term adverse sys-
temic effects are not generally observed among adults taking
low-to-medium doses, although effects on bone metabolism have
been reported for doses as lowas 400μgof beclomethasoneper day
or equivalent. At high-doses (usually >1000μg of beclometha-
sone per day or equivalent), the risks of side effects increase. The
most frequent of them are adrenal suppression, growth retarda-
tion in children, cataracts and elevated intraocular pressure. In
older adults with asthma, ICS reduce bone mineral density after
long-term, high-dose therapy (Irwin and Richardson, 2006). To
minimize these side effects, strategies that can achieve asthma con-
trol without using high-doses of ICS and step down treatment to
the lowest possible dose of ICS thatmaintains symptomcontrol are
desirable (Lemanske et al., 2001). In children, growth retardation
is a concern but some data suggest that pre-adolescent school-age
children who continue to receive long-term treatment with ICS
ultimately reach their normal predicted height (Agertoft and Ped-
ersen, 2000; Anonymous, 2000). ICS safety is affected by several
factors (Derendorf et al., 2006). On-site activation in the lung,
low oro-pharyngeal exposure and oral bioavailability, high pro-
tein binding and rapid systemic clearance improve safety of ICS
(Colice, 2006; Derendorf et al., 2006). Prodrugs that are activated
in the lungs but not in the oro-pharynx such as ciclesonide and
beclomethasone and new formulations and devices that increase
lung deposition can improve ICS safety (Colice, 2006; Derendorf
et al., 2006).
LEUKOTRIENE RECEPTOR ANTAGONISTS
Selective cysteinyl (Cys) LT1 receptor antagonists, commonly
known as LTRA, that have been approved for clinical use in asthma
include montelukast and zaﬁrlukast. Pranlukast is only marketed
in Japan and other Asian countries. Zileuton is a 5-lipoxygenase
(LO) inhibitor that has been approved for the prevention and
continuous treatment of asthma in adults and children 12 years
of age and older in the United Kingdom and USA. Zileuton it is
not available in other countries and its use is limited by a mod-
est but distinct incidence of hepatic enzyme elevation that is not
observed with montelukast. Five-lipoxygenase activating protein
(FLAP) inhibitors including 2190914 (AM-103) (Lorrain et al.,
2009; Bain et al., 2010) and GSK-2190915 have entered phase II
trials for the treatment of asthma (Sampson, 2009).
Montelukast is the most prescribed LTRA in Europe and North
America. Zaﬁrlukast was the ﬁrst LTRA that was approved in
Europe, is approved in adults and children with asthma 5 years
of age and older, but it is not frequently prescribed due to possi-
ble food and drug interactions, and the twice daily administration
regimen (Dahlen, 2006; Montuschi et al., 2007). Selective CysLT1
receptor antagonists and 5-LO inhibitors appear to have similar
efﬁcacy in short-term treatment studies and challenge models,
suggesting that most of the anti-asthmatic effects of anti-LTs are
due to CysLT1 antagonism (Dahlen, 2006).
Leukotriene receptor antagonists improve symptoms and lung
function, and reduce exacerbation rate, the use of SABA, and air-
way and blood eosinophilia in adults and children with asthma of
varying severity (Busse and Kraft, 2005; Dahlen, 2006; Montuschi
et al., 2007; Peters-Golden and Henderson, 2007; Montuschi and
Peters-Golden, 2010). In patients with persistent asthma who are
undertreated and remain symptomatic while taking SABA alone,
LTRA provide a prompt improvement in asthma control, although
low-dose ICS are generally more effective than LTRA as ﬁrst-line
maintenance treatment (Busse et al., 2001). In North America,
mono-therapy with LTRA is a common therapeutic option for
patients with mild persistent asthma (FitzGerald and Shahidi,
2010; Lougheed et al., 2010). However, ICS are generally preferred
(NAEPP National Asthma Education and Prevention Program:
Expert Panel Report III, 2007) due to their greater efﬁcacy as ﬁrst-
line agents in both adults and children with asthma (Szeﬂer et al.,
2005). Nonetheless, LTRA can be used as controllers in patients
who cannot tolerate ICS or prefer a non-steroid drug (FitzGerald
and Shahidi, 2010; Lougheed et al., 2010).
Leukotriene receptor antagonists are effective in reducing early
and late asthmatic responses induced by allergen inhalation in
adults (Roquet et al., 1997; Leigh et al., 2002) and children
(Phipatanakul et al., 2002), but these drugs are less effective than
ICS in reducing allergen-induced AHR (Leigh et al., 2002).
In Europe, LTRA are indicated for preventing exercise-induced
bronchoconstriction (Dahlen, 2006). Montelukast given at a dose
of 10mgonce daily protects against exercise-induced bronchocon-
striction over a 12-week period in adults with asthma (Leff
et al., 1998). This effect, observed as soon as 2 h after a sin-
gle oral dose of montelukast (10mg), is maintained up to 24 h
(Pearlman et al., 2006; Philip et al., 2007). Montelukast is more
effective that salmeterol in the chronic treatment of exercise-
induced bronchoconstriction over a period of 8weeks in adults
with mild asthma (Villaran et al., 1999). LTRA are also effec-
tive in exercise-induced bronchoconstriction in children (Melo
et al., 2003), although generally less effective than ICS in children
with exercise-induced bronchoconstrictionwith persistent asthma
(Grzelewski and Stelmach, 2009).
CysLT1 receptor antagonism and 5-LO activity inhibition pro-
tect against the reduction in FEV1 in response to aspirin challenge
(Dahlen, 2006) and improve asthma control in aspirin-sensitive
patients (Dahlen et al., 1998, 2002).
Add-on therapy with LTRA improves asthma control (Bjermer
et al., 2003; Price et al., 2003; Vaquerizo et al., 2003) and enables
a reduction in the dose of ICS required to control asthma (Lof-
dahl et al., 1999). However, combination treatment with LTRA
and ICS is generally less effective than combination of long-acting
β2-agonist (LABA) and ICS (Ducharme et al., 2006; Lemanske
et al., 2010), The steroid-sparing effect reduces the risk of side
effects causedby long-termadministrationof high-dose ICS (Price
et al., 2003). There is a high degree of variability in the therapeu-
tic response to LTRA in patients with asthma (Malmstrom et al.,
1999; Vaquerizo et al., 2003; Szeﬂer and Martin, 2010), but, to a
lesser extent, this is also true for ICS.
Leukotriene receptor antagonists are generally safe and well
tolerated. An association between LTRA and Churg–Strauss syn-
drome has been reported (Bibby et al., 2010). In most conﬁrmed
cases of Churg–Strauss syndrome reported, therapy with LTRA
was a suspect medication (Bibby et al., 2010). In the majority of
cases treated with a LTRA, Churg–Strauss syndrome could not
be explained by ICS suspension or pre-existing Churg–Strauss
syndrome (Bibby et al., 2010).
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NEW OUTCOME MEASURES IN ASTHMA RANDOMIZED
CLINICAL TRIALS: TOWARD A OMICS PROFILING
Asthma control, the primary goal of pharmacological treatment,
includes reduction of impairment and risk (NAEPP National
Asthma Education and Prevention Program: Expert Panel Report
III, 2007; Figure 1). Reduction of impairment implies preven-
tion of chronic asthma symptoms, use of SABA equal or less
than 2 days a week, maintenance of nearly normal lung func-
tion and normal activity (NAEPP National Asthma Education
and Prevention Program: Expert Panel Report III, 2007); reduc-
tion of risk implies prevention of recurrent asthma exacerba-
tions and decrease in lung function and optimal pharmaco-
logical therapy with minimal adverse effects (NAEPP National
Asthma Education and Prevention Program: Expert Panel Report
III, 2007). Conventional outcome measures used for assessing
asthma control are symptoms, use of SABAs for quick symptom
relief, limitation to normal activities due to asthma, lung func-
tion testing, AHR, and asthma exacerbations (NAEPP National
Asthma Education and Prevention Program: Expert Panel Report
III, 2007). Clinical trials for assessing efﬁcacy of anti-asthmatic
drugs are principally based on these conventional outcome mea-
sures. Although relevant and well-established outcome measures,
symptoms, lung function testing, AHR, and asthma exacerba-
tion rate do not reﬂect directly airway inﬂammation that is the
mainpathophysiological characteristic of asthma.Thismakes con-
ventional outcome measures not ideal for assessing the direct
effect of drugs for long-term asthma control that are primar-
ily anti-inﬂammatory and for studying the relationships between
persistent airway inﬂammation and airway remodeling. In other
words, conventional outcomes are indirect measures of airway
inﬂammation and lack sufﬁcient sensitivity. Bronchoscopy and
bronchial biopsy are the gold standard for assessing airway
inﬂammation, but these techniques are invasive and not gener-
ally indicated in patients with asthma who are at greater risk
for bronchospasm due to AHR. For these reasons, the iden-
tiﬁcation and validation of non-invasive biomarkers of airway
inﬂammation, to be used for the assessment of the asthmatic
patients and for monitoring of pharmacological response, is
FIGURE 1 | Objectives of pharmacological treatment of asthma. ICS,
inhaled corticosteroids; LTRA, leukotriene receptor antagonists.
a priority in asthma research and, more generally, in respiratory
research.
Non-invasive or semi-invasive techniques for assessing airway
inﬂammation in patients with asthma have been validated or are
under development (Tables 1 and 2). These include measurement
of FENO, measurement of eosinophils cell counts and biomole-
cules in sputum, measurement of biomolecules in exhaled breath
condensate (EBC), and electronic nose (Figure 2).
MEASUREMENT OF FENO
Measurement of FENO, a completely non-invasive technique for
assessing airway inﬂammation in patients with asthma, has been
approved in the clinical setting (Silkoff et al., 2004). This technique
is standardized, reproducible, and provides immediate results
(Bates and Silkoff, 2003; Barnes et al., 2010). Portable, hand-
held, FENO analyzers that enable on-site sampling are available
(Khalili et al., 2007; Menzies et al., 2007; Takalo et al., 2008).
Table 1 | Non-invasive monitoring of airway inflammation: current
techniques.
Technique Characteristics
Peak expiratory ﬂow rate
(PEFR)
Indirect measure
Airway
hyper-responsiveness (PC20)
Indirect measure
Fraction of exhaled nitric
oxide (FENO)
Surrogate marker; validated, standardized,
clinically approved, immediate results
Induced sputum Semi-invasive
Eosinophil counts Direct measure, validated, standardized
Biomolecules in sputum
supernatants
Biomarkers; not standardized, validation
required for immunoassays
PC20: “provocative dose” of an agent, like methacholine, causing a 20% fall in
forced expiratory volume in 1 s (FEV1).
Table 2 | Non-invasive monitoring of airway inflammation: innovative
techniques.
Technique Characteristics
Exhaled breath
condensate (EBC)
Non-invasive, not standardized
Measurement of
biomolecules
Biomarkers; some biomolecules measured
with reference analytical techniques,
validation required for most immunoassays
Metabolomics with
nuclear magnetic
resonance (NMR)
spectroscopy
Biomarkers; highly speciﬁc, quantitative,
analysis of multidimensional data requiring
algorithms for pattern recognition
Electronic nose (E-nose) Non-invasive, not standardized
Biomarkers; analysis ofmultidimensional data
requiring algorithms for pattern recognition
Breath analysis with
gas-chromatography/mass
spectrometry (GC/MS)
Biomarkers; highly speciﬁc, quantitative
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FIGURE 2 | Breath analysis with electronic nose. (A) An electronic nose (Cyranose 320, Smiths Detection, Pasadena, USA). (B) A typical response obtained
when electronic nose sensor array is exposed to a breath sample.
FENO correlates with eosinophilic inﬂammation and AHR before
corticosteroid treatment, is useful in asthma diagnosis, decreases
rapidly after anti-inﬂammatory treatment and predicts response,
increases during asthma exacerbations, and can be used to mon-
itor compliance (Bates and Silkoff, 2003; Barnes et al., 2010).
However, FENO only measures one component of the asthmatic
inﬂammatory response which is a complex pathophysiological
process and is affected by several factors including atopy and
gene polymorphisms (Bates and Silkoff, 2003). Moreover, single
breath FENO measurement is difﬁcult in preschool children and
the dose–response to ICS is steep and plateaus early (Bates and
Silkoff, 2003). In a single-blind, placebo-controlled trial, in which
97 adults with asthma who had been regularly receiving treatment
with ICSwere randomly assigned to have their glucocorticoid dose
adjusted on the basis of either FENO or based on conventional
guidelines, maintenance doses of ICS were signiﬁcantly reduced
(−270μg of ﬂuticasone per day, 95% CI, 112–430) in the FENO
group without compromising asthma control (Smith et al., 2005).
A systematic review aiming at assessing the efﬁcacy of tailoring
asthma interventions based on FENO compared to conventional
methods (symptoms and lung function tests) and including two
adult (Smith et al., 2005; Shaw et al., 2007) and four pediatric
studies (Pijnenburg et al., 2005; Fritsch et al., 2006; Szeﬂer et al.,
2008; de Jongste et al., 2009), reported no between-group differ-
ence for the primary outcome of asthma exacerbations or for other
asthma-related outcomes (symptoms, lung function tests, FENO;
Petsky et al., 2009). Post hoc analysis showed signiﬁcant reduction
in mean daily dose ICS in adults with asthma in whom treatment
was based on FENO in comparison to symptoms (mean difference
−450μg; 95% CI −677 to −223μg budesonide equivalent/day;
Petsky et al., 2009). This trendwas not observed in children or ado-
lescents with asthma in whom there was a signiﬁcant increase in
ICS dose in the FENO strategy group (mean difference of 140μg;
95% CI 29 to 251μg budesonide equivalent/day; Petsky et al.,
2009). However, the studies included in this meta-analysis dif-
fered as regard to deﬁnition of asthma exacerbations, FENO cut
off concentrations, duration of study, and the way in which FENO
was used to adjust therapy (Petsky et al., 2009). The role of FENO
measurement to tailor the dose of ICS is not currently deﬁned and
requires further studies.
SPUTUM EOSINOPHILS
Sputum induction is a semi-invasive technique for assessing air-
way inﬂammation. Measurement of sputum eosinophil and other
inﬂammatory cell counts is a direct, standardized, and validated
method for assessing airway inﬂammation (Djukanovic et al.,
2002; Efthimiadis et al., 2002; Paggiaro et al., 2002; Vignola et al.,
2002). Assessment of sputum inﬂammatory cells can be used to
identify asthma phenotypes and deﬁne those phenotypes which
respond to pharmacological treatment (Bakakos et al., 2011).
Elevated sputum eosinophilia (>3%) is frequently observed in
patients with asthma, although some patients have a predomi-
nant neutrophilic or combined phenotype (Wenzel, 2006; Gibson,
2009). Clinically useful applications of induced sputum analysis
include assessment of adequacy of ICS therapy and compliance,
long-term therapy management in asthma, oral corticosteroid
dose adjustment in refractory asthma and assessment of occupa-
tional asthma (Green et al., 2002; Chlumský et al., 2006; Jayaram
et al., 2006; Gibson, 2009). However, sputum induction is not
generally well accepted to patients, can cause bronchoconstriction
itself, requires processing of samples within 2 h and specialized
staff (Efthimiadis et al., 2002), and can be unfeasible in children
and patients with severe asthma. In a systematic review including
215 adults with asthma, assessment of sputum eosinophil counts
for asthma control signiﬁcantly reduced the number of patients
who had asthma exacerbations compared with tailored interven-
tions based on symptoms (52 versus 77; P = 0.0006), odds ratio
(OR) 0.36 (95% CI 0.20 to 0.64). Number needed to treat (NNT)
for beneﬁt was 6 (95% CI 4–32) over 52weeks (Petsky et al., in
press). Although the number of patients with asthma included in
this systematic review is relatively limited and the studies consid-
ered have a degree of heterogeneity, these ﬁndings indicate that
tailoring of treatment based on sputum eosinophils in adults with
asthma is effective in reducing asthma exacerbations (Petsky et al.,
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in press). Although unpractical to perform routinely, analysis of
sputum eosinophils is a semi-invasive technique for assessing air-
way inﬂammation that can provide an additional tool to guide the
management of patients with asthma (Bakakos et al., 2011).
INFLAMMATORY BIOMARKERS IN SPUTUM SUPERNATANTS
Several inﬂammatory biomarkers, including eosinophil-derived
proteins, NO-derived metabolites, eicosanoids, cytokines, and air-
way remodeling-associated proteins can be measured in sputum
supernatants in patients with asthma (Bakakos et al., 2011). How-
ever, measurement of biomolecules in sputum supernatants is
often affected by interferences between reagents used for sputum
processing (e.g., dithiothreitol) and immunoassays,which are gen-
erally used as analytical techniques. Immunoassays for measuring
biomolecules in sputum supernatants require validation before
this approach for assessing airway inﬂammation can be considered
for clinical applications.
INFLAMMATORY BIOMARKERS IN EXHALED BREATH CONDENSATE
Analysis of EBC is a non-invasive method for studying the compo-
sition of airway lining ﬂuid and has the potential for assessing res-
piratory inﬂammation (Montuschi, 2002). Several biomolecules
including leukotrienes (LTs), 8-isoprostane, prostaglandins (PGs),
hydrogenperoxide,NO-derived products, andhydrogen ions,have
beendetected in healthy subjects (Montuschi, 2007). Someof these
inﬂammatory mediators in EBC are elevated in patients with dif-
ferent respiratory diseases including asthma (Montuschi, 2007;
Horváth et al., 2005). As it is completely non-invasive, analysis of
EBC is suitable for longitudinal studies, is potentially useful for
assessing the response to pharmacological treatment, and might
also have a diagnostic value by identifying selective proﬁles of bio-
markers of lung diseases (Montuschi, 2002, 2007). Biomolecules,
including LTB4 (Montuschi et al., 2004), 8-isoprostane (Carpenter
et al., 1998; Syslová et al., 2008), PGE2 (Carpenter et al., 1998), and
smallmolecularweightmetabolites (deLaurentiis et al., 2008) have
been measured in EBC using reference analytical techniques such
asmass spectrometry or nuclearmagnetic resonance spectroscopy.
However, several methodological issues including standardization
of procedures for EBC analysis and validation of some analytical
techniques need to be addressed before EBC analysis can be con-
sidered in the clinical setting (Montuschi, 2007). Further research
in this area is warranted due to the relative lack of non-invasive
methods for assessing airway inﬂammation.
ELECTRONIC NOSE
Several volatile organic compounds (VOCs), including isoprene,
1,2-pentadiene, acetone, and ethane, have been identiﬁed in
exhaled breath in healthy subjects by gas-chromatography/mass
spectrometry (Phillips, 1997; Phillips et al., 1999). Identiﬁcation
of selective VOC patterns in exhaled breath is potentially useful as
a biomarker of asthma. An electronic nose is an artiﬁcial sensor
system that consists of an array of chemical sensors forVOC detec-
tion and an algorithm for pattern recognition (Röck et al., 2008;
Figure 2). The electronic nose discriminates between patients
with asthma and healthy subjects (Dragonieri et al., 2007; Mon-
tuschi et al., 2010) and between patients with asthma and chronic
obstructive pulmonary disease (Fens et al., 2009). The electronic
nose has been reported to have a high diagnostic performance that
can be increased when combined with FENO (Montuschi et al.,
2010). However, large studies are required to deﬁnitively estab-
lish the diagnostic performance of the electronic nose. Whether
this approach based on electronic nose will translate into an early
diagnosis of asthma and anovel non-invasive technique for asthma
phenotyping and management has to be clariﬁed.
BIOMARKERS OF AIRWAY REMODELING
Bronchoscopy with bronchial biopsies enables a direct assessment
of airway remodeling, but this technique is invasive and not gen-
erally indicated in patients with asthma who can be at higher
risk of bronchospasm due to AHR. Functional outcome mea-
sures including changes in pulmonary function and AHR over
time co-varies with airway structural changes, but these mea-
sures are not direct and speciﬁc, not sufﬁciently sensitive, and
the interactions are complex (Larsson, 2010). Several biomole-
cules which are pathophysiologically involved in airway structural
changes that characterize asthma have been measured in different
biological ﬂuids, but no speciﬁc validated inﬂammatory biomark-
ers of airway remodeling obtained from sputum, bronchoalveolar
lavage (BAL), blood, exhaled air, EBC, urine, or saliva are currently
available (James and Wenzel, 2007). Identiﬁcation of non-invasive
speciﬁc, sensitive, and validated biomarkers of airway remod-
eling would provide important information on disease severity
and progression in the individual patients with asthma and new
relevant outcome measures for assessing the effect of pharmaco-
logical treatment with potential implications for the management
of asthmatic patients.
Promising results have been reported with novel imaging
techniques and recent studies have demonstrated how struc-
tural airway and lung changes can be detected on computerized
tomography (Larsson, 2010).
ASTHMA CONTROL AND AIRWAY REMODELING
AIRWAY STRUCTURAL CHANGES IN ASTHMA
In patients with asthma, chronic airway inﬂammation is associ-
ated with structural changes known as airway remodeling (James
andWenzel, 2007) which include epithelial damagewith decreased
adhesion of epithelial cells, known as epithelial fragility, reticular
basement membrane thickening, subepithelial ﬁbrosis with extra-
cellularmatrix deposition,hypertrophy andhyperplasia of smooth
muscle cells, recruitment and activation of myoﬁbroblasts, gob-
let cell hyperplasia, hypertrophy of submucosal mucous glands,
angiogenesis, and likely direct transformation of epithelial cells
into mesenchymal cells (Bai, 2010; Bergeron et al., 2010; Halwani
et al., 2010). These structural changes contribute to thickening of
airway walls and, consequently, lead to airway obstruction, AHR,
edema, and mucus hypersecretion (Bergeron et al., 2010).
AIRWAY REMODELING: PATHOPHYSIOLOGICAL IMPLICATIONS IN
ASTHMA
Airway remodeling contributes to asthma persistence, airﬂow
obstruction, lung function decline, and clinical severity (Bai,
2010), does not resolve spontaneously (Royce and Tang, 2009),
and is commonly attributed to an underlying chronic inﬂamma-
tory process (Homer and Elias, 2000; Murray, 2008; Janson, 2010).
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However, relationships between airway inﬂammation and remod-
eling are not completely known.Airway remodeling is a key feature
of the 5–10%of the asthmatic patientswith severe disease (Girodet
et al., 2011), but can also be present in patients withmild persistent
asthma (Royce and Tang, 2009; Larsson, 2010). Some remodeling
changes such as reticular basement membrane thickening (Saglani
et al., 2007) and increase in airway smooth muscle mass (Regamey
et al., 2008) can occur early in the course of asthma pathogenesis
(Bush, 2008; Royce and Tang, 2009). Airway remodeling is par-
tially reversible in mild persistent asthma but mostly irreversible
in severe persistent asthma (Halwani et al., 2010). Early diagnosis
and prevention of airway remodeling has the potential to decrease
disease severity, improve control and prevent disease expression
(Bergeron et al., 2010).
ASSESSMENT OF DRUG EFFECTS ON ASTHMA AIRWAY REMODELING
Assessment of the effects of ICS and other anti-inﬂammatory
drugs on airway remodeling in patients with asthma is difﬁcult
due to the relative lack of prospective, randomized, double-blind,
controlled, long-term studies aiming at assessing the effect of
pharmacological treatment on clinical and physiological outcomes
(Walters et al., 2007); the lack of non-invasive validated biomark-
ers for assessing airway remodeling that requires bronchoscopic
and biopsy studies; the relative inadequacy of predictive experi-
mental models for testing the anti-remodeling effects of drugs; the
different effect of pharmacological treatment on different types of
airway structural and inﬂammatory cells and mediators that can
be involved in the airway remodeling process (Walters et al., 2007).
EFFECTS OF ICS ON ASTHMA CONTROL, AIRWAY INFLAMMATION, AND
AIRWAY REMODELING
Regular treatment with ICS may partly have a beneﬁcial effect
on airway remodeling in asthma. In a 24-month random-
ized, prospective, parallel trial in patients with mild-to-moderate
asthma, adjustment of ICS dose according to AHR in addition to
existing guidelines (AHR strategy) was more effective than adjust-
ment of ICS based on existing guidelines only (reference strategy)
in controlling asthma, reducing chronic airway inﬂammation, and
reducing airway remodeling as reﬂected by reticular basement
membrane thickness (Sont et al., 1999). However, the greater efﬁ-
cacy observed in the AHR strategy group required higher ICS
doses, the median difference in treatment with ICS being ±400μg
per day (Sont et al., 1999).
In a 12-month double-blind, randomized, placebo-controlled,
parallel-group study in mild-to-moderate steroid-naive patients
with asthma, inhaled ﬂuticasone propionate at a dose of 750μg
b.i.d. reduced BAL inﬂammatory cells and improved FEV1 after
3months of treatment with no further improvement at 12months
(Ward et al., 2002). By contrast, reduction in reticular basement
membrane thickness, a component of airway remodeling,was only
observed at 12months (Ward et al., 2002). There was a progres-
sive reduction in AHR throughout the study with the larger effect
associatedwith the later improvement in airway remodeling (Ward
et al., 2002).
Taken together, this evidence suggests that airway inﬂamma-
tion, AHR, and airway remodeling are interrelated and improve
with ICS (Ward et al., 2002, 2005). Effects of ICS treatment on
different outcome measures do not occur at the same time, with
prolonged treatment required for achieving maximal beneﬁt in
airway remodeling and AHR (Ward et al., 2002, 2005). Deter-
mining the appropriate dose of ICS only based on clinical and
functional outcomes, as speciﬁed in current international guide-
lines, and even on direct inﬂammatory outcome measures may
be over simplistic and support the view that regular treatment
with ICS should be started early and be on long-term basis, even
in patients with relatively mild asthma (Ward et al., 2002, 2005).
However, measurement of reticular basement membrane thick-
ness and even AHR for ICS dose-ﬁnding and guiding duration
of treatment is not suitable for routine longitudinal assessment
of patients with asthma. Moreover, reticular basement membrane
thickness is one component, although relevant, of airway remod-
eling, a complex process, which is only partially responsive to ICS
(Murray, 2008). For instance, treatment with oral corticosteroids
for 2 weeks does not affect type I and type III collagen deposition,
a typical feature of airway remodeling, or the expression of trans-
forming growth factor-β, a proﬁbrotic cytokine that stimulates
ﬁbroblasts to secrete extracellular matrix proteins including col-
lagen I and III (Chakir et al., 2003). By contrast in another study,
inhaled beclomethasone at a dose of 800 μg daily for 6months
decreased type III collage deposition in patients with asthma
(Hoshino et al., 1999).
Whether ICS have a predominant positive or negative effect on
airway epithelial cells in patients with asthma is not completely
deﬁned (Walters et al., 2007). Treatment with ICS decreases BAL
epithelial cell counts concomitant with amelioration of clinical
outcomes, possibly reﬂecting normalization of asthma epithelial
fragility (Walters et al., 2007). By contrast, the epidermal growth
factor pathway that is up-regulated in epithelial cells in patients
with asthma seems to be resistant to ICS treatment (Puddicombe
et al., 2000; Polosa et al., 2002). In vitro studies show that ﬂuti-
casone propionate, at therapeutic concentrations, is able to revert
myoﬁbroblasts to a normal phenotype (Cazes et al., 2001), but
data on the effect of ICS on airway smooth muscle cells in vivo are
not available (Murray, 2008).
To summarize, ICS have a beneﬁcial effect on some, but not all,
components involved in airway remodeling in asthma (Murray,
2008). In analogy to ICS therapeutic effects on diverse outcomes
(clinical, functional, AHR, airway inﬂammation, airway remodel-
ing) that occur at different times and have differing dose–response
relationships (Walters et al., 2007), different aspects of airway
remodeling might have different responses and timescales to ICS
(Ward et al., 2002, 2005).
NON-STEROIDAL DRUGS FOR AIRWAY REMODELING IN ASTHMA
Data on the effectiveness of LTRA, phosphodiesterase inhibitors,
mast cell tryptase inhibitors, and peroxisome proliferator-
activated receptor-γ agonists in the treatment or prevention of air-
way remodeling are limited (Royce and Tang, 2009). In an animal
model of human asthma, montelukast, a LTRA, prevents allergen-
induced airway changes and reverses structural changes includ-
ing airway smooth muscle cell layer thickening and subepithelial
ﬁbrosis, that are not affected by corticosteroid treatment (Hender-
son et al., 2006). In one biopsy study, montelukast (10mg once
daily for 8weeks) reduced airway myoﬁbroblast accumulation in
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patients with asthma following low-dose allergen challenge (Kelly
et al., 2006). More studies are required to determine the clini-
cal relevance of these ﬁndings with LTRA in preventing airway
remodeling and/or reversing established airway structural changes
in patients with asthma.
A better understanding of airway remodeling in asthma is likely
to prompt the identiﬁcation and development of new pharmaco-
logical therapies for asthma beyond control of symptoms, lung
function, and inﬂammation (Royce and Tang, 2009). Modulation
of the asthmatic airway remodeling will probably become an even
more important endpoint in the near future (Sandström, 2010).
PHARMACOLOGICAL STRATEGIES IN MILD PERSISTENT
ASTHMA: CONTINUOUS OR ON-DEMAND TREATMENT
CONTROLLED RANDOMIZED CLINICAL TRIALS
Patients with mild asthma who do not perceive the need for
daily therapy may be using their treatment intermittently. Three
studies compared regular versus on-demand treatment for mild
persistent asthma, the Improving Asthma Control Trial (IMPACT;
Boushey et al., 2005), the Beclomethasone plus Salbutamol Treat-
ment (BEST) study (Papi et al., 2007), and the Helsinki Early
Intervention Childhood Asthma Study (Turpeinen et al., 2008).
In the IMPACT study, a 12-month, double-blind, double-
dummy, parallel-group trial, 225 adults with long-standing mild
persistent asthma were randomized to receive daily treatment with
inhaled budesonide (200μg b.i.d.), oral zaﬁrlukast (20mg b.i.d.),
or placebo (Boushey et al., 2005).All patientswere instructed in the
use of intermittent short-course corticosteroid treatment based on
a high-dose of inhaled budesonide (800μg b.i.d. for 10 days) or
oral prednisone (0.5mg per kilogram of body weight per day for
5 days) guided by a symptom-based action plan (Boushey et al.,
2005). No signiﬁcant between-group differences were found in
change in two-week average morning PEF from randomization
to the end of the trial, the primary outcome measure, quality of
life, and asthma exacerbations (Boushey et al., 2005). However,
greater improvements in pre-bronchodilator FEV1, AHR, sputum
eosinophils, FENO, and symptom-free days were observed in the
budesonide group (Boushey et al., 2005; Figure 3). This study
indicates that treating mild persistent asthma with short, intermit-
tent courses of inhaled or oral corticosteroids taken as symptoms
worsen is possible (Boushey et al., 2005). However, it should be
noted that continuous treatment with inhaled budesonide was
superior to intermittent treatment with corticosteroids in improv-
ing outcomemeasures of airway inﬂammation. In particular, at the
end of the study, the group of asthmatic patients that received reg-
ular treatment with ICS had reduced sputum eosinophil counts
(P < 0.03), whereas those asthmatic patients who received inter-
mittent treatment with corticosteroids had increased sputum
eosinophil cell counts (P < 0.03) andnodifferencewas observed in
the zaﬁrlukast group (P = 0.71). Between-group differences were
highly signiﬁcant (P = 0.007). A similar trend was observed with
FENO. These data not only demonstrate the different efﬁcacy on
airway inﬂammatory outcomes between the two pharmacologi-
cal strategies (regular versus on-demand), but also indicate that
airway inﬂammation increases if not regularly treated with ICS.
Continuous treatment with inhaled budesonide also produced
a signiﬁcant improvement in AHR that was not observed with
FIGURE 3 | Pharmacological strategies for treatment of persistent mild
asthma: the Improving Asthma ControlTrial (IMPACT; Boushey et al.,
2005).
intermittent treatment with corticosteroids or continuous treat-
mentwith zaﬁrlukast. These effectsmight have important implica-
tions in themanagement of patientswith asthmaas controlling air-
way inﬂammation andAHRmight have a role in preventing and/or
reducing the progression of airway remodeling and, consequently,
worsening of symptoms and lung function (Canonica, 2006;
Murray, 2008).
In the BEST study, a 6-month, double-blind, double-dummy,
randomized, parallel-group trial, 455 patients with mild persis-
tent asthma were randomly assigned to receive one of the four
inhaled treatments: placebo twice daily plus on-demand combina-
tion therapy (250μg of beclomethasone and 100μg of salbutamol
in a single inhaler); placebo twice daily plus on-demand therapy
(100μg of salbutamol); regular beclomethasone therapy (250μg
twice daily) plus salbutamol (100μg) on-demand; or regular com-
bination therapy (250μg of beclomethasone and 100μg of salbu-
tamol in a single inhaler) twice daily plus salbutamol on-demand
(Papi et al., 2007). The morning PEF during the last 2 weeks of
the 6-month treatment period, which was the primary outcome,
was signiﬁcantly higher and the number of exacerbations during
the 6-month treatment was signiﬁcantly lower in the on-demand
combination therapy group than in the on-demand salbutamol
therapy group, but the values in the on-demand combination
therapy group were not signiﬁcantly different from those in the
groups receiving regular beclomethasone therapy or regular com-
bination therapy (Papi et al., 2007). These data would suggest that
the symptom-driven use of a combination of inhaled beclometha-
sone and salbutamol would be as effective as regular use of inhaled
beclomethasone twice daily inpatientswithmildpersistent asthma
(Papi et al., 2007). However, no biomarker of airway inﬂammation
wasmeasured in this study. For this reason, it is not knownwhether
these pharmacological strategies are equivalent for controlling air-
way inﬂammation. Moreover, the non-inferiority level for the
primary outcome was set at 10%, a value which is rather high
for non-inferiority studies. The maximum difference considered
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to indicate between-group clinical equivalence corresponded to
40 L/min (10% of the expected mean PEF of 400 L/min at the end
of the study; Papi et al., 2007). Although this limit was selected
on the basis of guidelines suggesting that therapy should not be
changed if PEF varies by less than 20% (NAEPP National Asthma
Education and Prevention Program: Expert Panel Report II, 1997),
it is not known whether such a difference in mean PEF has clinical
consequences.
In the Helsinki Early Intervention Childhood Asthma Study, a
18-month controlled, randomized, double-blind, parallel-group,
intervention trial, 176 children aged 5–10 years with newly diag-
nosed asthma were randomly assigned to three treatment groups:
(1) regular treatment with budesonide (100–400μg twice daily)
for months 1-18; (2) regular treatment with budesonide for
months 1–6, then budesonide for exacerbations as-needed for
months 7–18; or (3) disodium cromoglycate (10mg t.d.s.) for
months 1–18 (Turpeinen et al., 2008). Compared with disodium
cromoglycate the initial regular budesonide treatment resulted
in a signiﬁcantly improved lung function, fewer asthma exacer-
bations and a small but signiﬁcant decline in growth velocity.
Duringmonths 7–18, childrenwith asthmawhowere being receiv-
ing continuous treatment with budesonide had signiﬁcantly fewer
asthma exacerbations compared to those in the other groups
(Turpeinen et al., 2008). No signiﬁcant between-group differences
were observed in the morning PEF, the primary efﬁcacy variable
(Turpeinen et al., 2008). The results of this study show that contin-
uous treatment with budesonide is more effective in controlling
asthma exacerbation but less tolerated than a therapeutic strat-
egy based on intermittent use of budesonide given on-demand
(Turpeinen et al., 2008). In analogy to the BEST study, the effects
of the different pharmacological strategies on outcomes reﬂect-
ing airway inﬂammation (e.g., FENO and sputum eosinophil cell
counts) were not assessed.
ADVANTAGES AND DISADVANTAGES
The studies discussed above are not directly comparable due to
differences in study population, study design, and medications
used. The conclusions are not univocal and support the concept
that different therapeutic strategies with apparently similar efﬁ-
cacy, but likely different safety, can be used in the treatment of
mild persistent asthma. On-demand treatment is certainly more
accepted by patients with mild persistent asthma who have infre-
quent symptoms as this strategy helps in overcoming a possible
poor compliance and a common “steroid-phobia” observed with
a regular treatment. Considerations on the economic burden and
side effects of a chronic controller therapy can further contribute to
favor a self-management plan of symptom-driven treatment, espe-
cially in young patients who may require life-long treatment with
ICS. However, even if on-demand treatment seems to have a sim-
ilar, but not completely equivalent, efﬁcacy on clinical and func-
tional outcomes, it does not suppress chronic airway inﬂammation
or theAHRassociatedwith asthma, as shown in the IMPACT study
(Boushey et al., 2005). Thus, there is the possibility that patients
without a regular treatment with ICS may develop a more severe
asthma accompanied by airway remodeling (Janson, 2010) and
a progressive loss of lung function (Fabbri, 2005). However, the
possible clinical and functional consequences of persistent, not
controlled, airway inﬂammation in patients with asthma have to
be established (Lazarus,2006).Moreover, it has also be noticed that
current asthma therapies, including ICS, are successful in treating
airway inﬂammation, but do not speciﬁcally target the remodeling
process, so that airway structural changes progress despite optimal
control of inﬂammation, and airway remodeling is not eradicated
or prevented despite widespread use of anti-inﬂammatory treat-
ments (Royce and Tang, 2009). More generally, the relationships
between asthma symptoms, lung function, AHR, airway inﬂam-
mation and remodeling, the impact of airway inﬂammation and
remodeling on asthma severity and progression, and the effects
of pharmacological treatment on these outcomes and the nat-
ural history of asthma require further research. Persistent airway
inﬂammation has been described in patients with complete clini-
cal remission of asthma (van den Toorn et al., 2001). The clinical
implications of this ﬁnding have to be clariﬁed.
CHOOSING THE OUTCOME MEASURES
The choice of the outcome measures that have to be included in
clinical trials evaluating different therapeutic strategies for asthma
is important. Morning PEF, which was the primary outcome mea-
sure in both IMPACT and BEST studies, could not be a sufﬁciently
sensitive efﬁcacy parameter for assessing asthma control in adults,
as already shown in children (Anonymous, 2000; Turpeinen et al.,
2008). The assessment of asthma control should incorporate not
only outcomes reﬂecting current clinical control, such as symp-
toms, reliever use and lung function, and future risk, such as
exacerbations and lung function decline (Taylor et al., 2008), but
also reﬂecting airway inﬂammation. Drugs for asthma control,
which are principally anti-inﬂammatory, are not currently assessed
on the basis of their effects on inﬂammatory parameters. The
reasons for that are related to the relative lack of validated non-
invasive biomarkers of airway inﬂammation, but also involves a
skeptical attitude about their biological relevance supported by
recent meta-analyses based on heterogeneous, relatively limited
data (Petsky et al., 2009, in press). Part of this skepticism rely upon
the overwhelming number of potential non-invasive biomarkers
of airway inﬂammation that have been proposed, with evidence
for clinical utility for only two of them, FENO and sputum
eosinophil counts. More validated biomarkers of inﬂammation
are warranted. On the other hand, drugs for asthma control are
not currently assessed on the basis of their primary effect, which
is anti-inﬂammatory, but on clinical and functional outcomes.
Assessing drugs for asthma control based on direct outcome mea-
sures of airway inﬂammation would likely lead to a more rational
pharmacological intervention.
EFFECTS ON NATURAL HISTORY OF ASTHMA
Continuous treatment with ICS, alone or in combination with
other anti-asthmatic drugs, achieves and maintains asthma con-
trol, although there is no agreement that this pharmacological
strategy prevents progressive decline in lung function over time
(Anonymous, 2000; Pauwels et al., 2003). Both the IMPACT and
BEST studies are likely too short to formally address this issue and
longer controlled randomized clinical trials are required to prop-
erly assess whether airway inﬂammation must be suppressed over
time to prevent the progression of asthma.
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Treatment with ICS likely decreases the rate of FEV1 decline,
although this is currently difﬁcult to establish due to the lack
of randomized double-blind controlled studies that show such
an effect (Janson, 2010). Early treatment with ICS can result in
long-lasting control of patients with mild asthma (Haahtela et al.,
1994; Selroos et al., 1995). Maintenance therapy generally requires
a reduced dose, but discontinuation of treatment is often accom-
panied by asthma exacerbation (Haahtela et al., 1994). In both
adults (Haahtela et al., 1994; Selroos et al., 1995) and children
(Agertoft and Pedersen, 1994) with asthma, ICS effect was nega-
tively correlated with duration of disease as patients with shorter
duration of asthma symptoms had a greater improvement in lung
function. Two studies in infants and children with wheezing and
risk factors for developing asthma indicate that ICS donot alter the
natural history of the disease (Bisgaard et al., 2006; Guilbert et al.,
2006). However, asthma has long-term effects on lung function
as indicated by the Copenhagen City Heart Study that showed
greater decline rates in FEV1 over time in patients with asthma
compared with those observed in non-asthmatic subjects (Lange
et al., 1998). These asthma-related effects on lung function could
be due to persistent, uncontrolled, airway inﬂammation (Murray,
2008; Janson, 2010).
A PERSONALIZED THERAPEUTIC APPROACH
Whether all patients with mild persistent asthma should receive
daily long-term treatment with ICS or an alternative anti-
inﬂammatory drug is debated. It is likely that asthma, even within
the same severity class, is a more heterogeneous disease than was
previously recognized and that current treatment guidelines need
a ﬁne-tuning change (Lazarus, 2006). Patients with mild asthma
who have their disease well controlled by regular treatment with
ICS might be treated with only on-demand treatment plan as an
intermediate step toward the suspension of controller medication
(Fabbri, 2005). These patients require a strict monitoring to estab-
lish the efﬁcacy of the on-demand treatment in controlling asthma.
They likely represent only a select subgroup of patients with mild
asthma in whom the on-demand treatment might be successfully
adopted.
CONCLUSIONS
Until the relationship between symptoms, lung function tests,
AHR, inﬂammatory biomarkers, and longer-termvariables such as
asthma exacerbations and airway remodeling is better understood,
the regular treatment seems to be generally more appropriate than
on-demand therapy to warrant a greater control of asthma.
Classiﬁcation of asthma based on disease severity as recom-
mended by national and international guidelines remains a cor-
nerstone in the management of patients with asthma and data
obtained from randomized clinical trials remain the best way for
assessingdrug efﬁcacy and safety.However, the increasing evidence
for heterogeneity of asthma, the growing emphasis on asthma sub-
phenotypes, including molecular phenotypes identiﬁed by omics
technologies, and their possible implications in terms of differ-
ent asthma severity and progression and therapeutic response, are
changing the paradigmof treating patients with asthma only based
on classiﬁcation of their disease severity to a pharmacological
strategy more focused on the individual asthmatic patient. Fol-
lowing a common trend in medicine, pharmacological treatment
of asthma is going toward a personalized approach.
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